These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 9177957)

  • 1. D2-dopamine-receptor occupancy during treatment with haloperidol decanoate.
    Scherer J; Tatsch K; Albus M; Schwarz J; Mager T; Oertel WH
    Eur Arch Psychiatry Clin Neurosci; 1997; 247(2):104-6. PubMed ID: 9177957
    [TBL] [Abstract][Full Text] [Related]  

  • 2. D2 dopamine receptor occupancy during low-dose treatment with haloperidol decanoate.
    Nyberg S; Farde L; Halldin C; Dahl ML; Bertilsson L
    Am J Psychiatry; 1995 Feb; 152(2):173-8. PubMed ID: 7840348
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Haloperidol serum concentrations and D2 dopamine receptor occupancy during low-dose treatment with haloperidol decanoate.
    Regenthal R; Künstler U; Junhold U; Preiss R
    Int Clin Psychopharmacol; 1997 Sep; 12(5):255-61. PubMed ID: 9466159
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Delayed normalization of central D2 dopamine receptor availability after discontinuation of haloperidol decanoate. Preliminary findings.
    Nyberg S; Farde L; Halldin C
    Arch Gen Psychiatry; 1997 Oct; 54(10):953-8. PubMed ID: 9337776
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Iodine-123-iodobenzamide SPECT assessment of dopamine D2 receptor occupancy in riperidone-treated schizophrenic patients.
    Dresel S; Tatsch K; Dähne I; Mager T; Scherer J; Hahn K
    J Nucl Med; 1998 Jul; 39(7):1138-42. PubMed ID: 9669383
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Subjective experience and D2 receptor occupancy in patients with recent-onset schizophrenia treated with low-dose olanzapine or haloperidol: a randomized, double-blind study.
    de Haan L; van Bruggen M; Lavalaye J; Booij J; Dingemans PM; Linszen D
    Am J Psychiatry; 2003 Feb; 160(2):303-9. PubMed ID: 12562577
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Double-blind olanzapine vs. haloperidol D2 dopamine receptor blockade in schizophrenic patients: a baseline-endpoint.
    Bernardo M; Parellada E; Lomeña F; Catafau AM; Font M; Gómez JC; López-Carrero C; Gutiérrez F; Pavía J; Salamero M
    Psychiatry Res; 2001 Aug; 107(2):87-97. PubMed ID: 11530275
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment response to olanzapine and haloperidol and its association with dopamine D receptor occupancy in first-episode psychosis.
    Zipursky RB; Christensen BK; Daskalakis Z; Epstein I; Roy P; Furimsky I; Sanger T; Kapur S
    Can J Psychiatry; 2005 Jul; 50(8):462-9. PubMed ID: 16127964
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A practical loading dose method for converting schizophrenic patients from oral to depot haloperidol therapy.
    Wei FC; Jann MW; Lin HN; Piao-Chien C; Chang WH
    J Clin Psychiatry; 1996 Jul; 57(7):298-302. PubMed ID: 8666571
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dopamine D2/3 receptor binding potential and occupancy in midbrain and temporal cortex by haloperidol, olanzapine and clozapine.
    Tuppurainen H; Kuikka JT; Viinamäki H; Husso M; Tiihonen J
    Psychiatry Clin Neurosci; 2009 Aug; 63(4):529-37. PubMed ID: 19496999
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vivo 123I IBZM SPECT imaging of striatal dopamine-2 receptor occupancy in schizophrenic patients treated with olanzapine in comparison to clozapine and haloperidol.
    Tauscher J; Küfferle B; Asenbaum S; Fischer P; Pezawas L; Barnas C; Tauscher-Wisniewski S; Brücke T; Kasper S
    Psychopharmacology (Berl); 1999 Jan; 141(2):175-81. PubMed ID: 9952042
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized clinical trial of haloperidol decanoate and fluphenazine decanoate in the outpatient treatment of schizophrenia.
    Chouinard G; Annable L; Campbell W
    J Clin Psychopharmacol; 1989 Aug; 9(4):247-53. PubMed ID: 2570086
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A clinical trial comparing intramuscular haloperidol decanoate and oral haloperidol in chronic schizophrenic patients: efficacy, safety, and dosage equivalence.
    Vasavan Nair NP; Suranyi-Cadotte B; Schwartz G; Thavundayil JX; Achim A; Lizondo E; Nayak R
    J Clin Psychopharmacol; 1986 Feb; 6(1 Suppl):30S-37S. PubMed ID: 3514689
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term maintenance therapy with quetiapine versus haloperidol decanoate in patients with schizophrenia or schizoaffective disorder.
    Glick ID; Marder SR
    J Clin Psychiatry; 2005 May; 66(5):638-41. PubMed ID: 15889952
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Positron emission tomography measurement of dopamine D₂ receptor occupancy in the pituitary and cerebral cortex: relation to antipsychotic-induced hyperprolactinemia.
    Arakawa R; Okumura M; Ito H; Takano A; Takahashi H; Takano H; Maeda J; Okubo Y; Suhara T
    J Clin Psychiatry; 2010 Sep; 71(9):1131-7. PubMed ID: 20361897
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predicting haloperidol occupancy of central dopamine D2 receptors from plasma levels.
    Fitzgerald PB; Kapur S; Remington G; Roy P; Zipursky RB
    Psychopharmacology (Berl); 2000 Mar; 149(1):1-5. PubMed ID: 10789875
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High levels of dopamine D2 receptor occupancy with low-dose haloperidol treatment: a PET study.
    Kapur S; Remington G; Jones C; Wilson A; DaSilva J; Houle S; Zipursky R
    Am J Psychiatry; 1996 Jul; 153(7):948-50. PubMed ID: 8659621
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].
    Llorca PM; Miadi-Fargier H; Lançon C; Jasso Mosqueda G; Casadebaig F; Philippe A; Guillon P; Mehnert A; Omnès LF; Chicoye A; Durand-Zaleski I
    Encephale; 2005; 31(2):235-46. PubMed ID: 15959450
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Striatal dopaminergic D2 receptor occupancy and clinical efficacy in psychosis exacerbation: a 123I-IBZM study with ziprasidone and haloperidol.
    Corripio I; Catafau AM; Perez V; Puigdemont D; Mena E; Aguilar Y; Carrió I; Alvarez E
    Prog Neuropsychopharmacol Biol Psychiatry; 2005 Jan; 29(1):91-6. PubMed ID: 15610950
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Striatal dopamine-2 receptor occupancy in psychotic patients treated with risperidone.
    Küfferle B; Brücke T; Topitz-Schratzberger A; Tauscher J; Gössler R; Vesely C; Asenbaum S; Podreka I; Kasper S
    Psychiatry Res; 1996 Nov; 68(1):23-30. PubMed ID: 9027930
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.